Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 12/2023

Open Access 08-11-2023 | Crizotinib

Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor

Authors: Qi-An Wang, Huan-Wu Chen, Ren-Chin Wu, Chiao-En Wu

Published in: Current Treatment Options in Oncology | Issue 12/2023

Login to get access

Opinion statement

Inflammatory myofibroblastic tumor (IMT), characterized by intermediate malignancy and a propensity for recurrence, has presented a formidable clinical challenge in diagnosis and treatment. Its pathological characteristics may resemble other neoplasms or reactive lesions, and the treatment was limited, taking chemotherapies as the only option for those inoperable. However, discovering anaplastic lymphoma kinase (ALK) protein expression in approximately 50% of IMT cases has shed light on a new diagnostic approach and application of targeted therapies. With the previous success of combating ALK+ non-small-cell lung cancers with ALK tyrosine kinase inhibitors (TKIs), crizotinib, a first-generation ALK-TKI, was officially approved by the U.S. Food and Drug Administration in 2020, to treat unresectable ALK+ IMT. After the approval of crizotinib, other ALK-TKIs, such as ceritinib, alectinib, brigatinib, and lorlatinib, have proven their efficacy on ALK+ IMT with sporadic case reports. The sequential treatments of targeted therapies in may provide the insight into the choice of ALK-TKIs in different lines of treatment for unresectable ALK+ IMT.
Appendix
Available only for authorised users
Literature
1.
2.
Häusler M, et al. Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol. 2003;34(3):253–62.PubMedCrossRef
3.
Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61(4):428–37.PubMedCrossRef
4.
Patnana M, et al. Inflammatory pseudotumor: the great mimicker. AJR Am J Roentgenol. 2012;198(3):W217–27.PubMedCrossRef
5.
Fletcher, C.D.M., K.K. Unni, and F. Mertens, Pathology and Genetics of tumours of soft tissue and bone. 3rd ed. Vol. 5. 2002: World Health Organization.
6.
Coffin CM, et al. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19(8):859–72.PubMedCrossRef
7.
Webb TR, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331–56.PubMedPubMedCentralCrossRef
8.
9.
Karnak I, et al. Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg. 2001;36(6):908–12.PubMedCrossRef
10.
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113(2):70–84.PubMedCrossRef
11.
12.
Fletcher CDM. Diagnostic histopathology of tumors. New York, Churchill, Livingstone; 1500-1501.
13.
Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31(4):509–20.PubMedCrossRef
14.
Bennett JA, et al. Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. Mod Pathol. 2017;30(10):1489–503.PubMedCrossRef
15.••
Antonescu, C.R., et al., WHO classification of tumours: soft tissue and bone tumours. 5th ed. Vol. 3. 2020, Lyon: International Agency for Research on cancer. The newest update of WHO classification, presenting the guideline of approaching IMT.
16.
Fu GX, et al. Inflammatory myofibroblastic tumor: a demographic, clinical and therapeutic study of 92 cases. Math Biosci Eng. 2019;16(6):6794–804.PubMedCrossRef
17.
Panagiotopoulos N, et al. Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm? J Thorac Dis. 2015;7(5):908–11.PubMedPubMedCentral
18.
Al-Obaidi A, et al. Inflammatory myofibroblastic tumor of the lung: an extremely rare condition in adults. Cureus. 2019;11(12):e6432.PubMedPubMedCentral
19.
Choi AH, et al. Inflammatory myofibroblastic tumor of the small bowel mesentery: an unusual cause of abdominal pain and uveitis. J Gastrointest Surg. 2011;15(4):584–8.PubMedCrossRef
20.
Gros L, et al. Inflammatory myofibroblastic tumour: state of the art. Cancers (Basel). 2022;14(15)
21.
Alaggio R, et al. Inflammatory myofibroblastic tumors in childhood: a report from the Italian cooperative group studies. Cancer. 2010;116(1):216–26.PubMedCrossRef
22.•
Siemion K, et al. What do we know about inflammatory myofibroblastic tumors? – a systematic review. Advan Med Sci. 2022;67(1):129–38. A systemic review on the update of kowledge regarding IMT diagnosis.CrossRef
23.
Favini F, et al. Inflammatory myofibroblastic tumor of the conjunctiva: response to chemotherapy with low-dose methotrexate and vinorelbine. Pediatr Blood Cancer. 2010;54(3):483–5.PubMedCrossRef
24.
Kube S, et al. Inflammatory myofibroblastic tumors-a retrospective analysis of the cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2018;65(6):e27012.PubMedCrossRef
25.
Baldi GG, et al. Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): a retrospective analysis within the Italian rare tumours network (RTR). J Clin Oncol. 2019;37(15):e22545–5.CrossRef
26.
Zhu Z, et al. Inflammatory myofibroblastic tumors in paranasal sinus and nasopharynx: a clinical retrospective study of 13 cases. Biomed Res Int. 2018;2018:7928241.PubMedPubMedCentralCrossRef
27.
Baldi GG, et al. The activity of chemotherapy in inflammatory myofibroblastic tumors: a multicenter. Eur Retrospective Case Series Anal Oncol. 2020;25(11):e1777–84.
28.
Soyer T, et al. Surgical treatment of childhood inflammatory myofibroblastic tumors. Eur J Pediatr Surg. 2017;27(4):319–23.PubMedCrossRef
29.
30.
Sanders BM, et al. Inflammatory pseudotumor of the alimentary tract: clinical and surgical experience. J Pediatr Surg. 2001;36(1):169–73.PubMedCrossRef
31.
Lindberg MR. Diagnostic pathology: soft tissue Tumors. 3rd ed; 2019.
32.
Mocellin S. Soft tissue tumors: a practical and comprehensive guide to sarcomas and benign neoplasms. Springer Cham; 2020.
33.
Elmadi A, et al. Pseudotumeur inflammatoire pulmonaire chez un enfant. Journal de Pédiatrie et de Puériculture. 2011;24(2):69–71.CrossRef
34.
35.
36.
Rohrlich P, et al. Interleukin-6 and interleukin-1 beta production in a pediatric plasma cell granuloma of the lung. Am J Surg Pathol. 1995;19(5):590–5.PubMedCrossRef
37.
Chun YS, et al. Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. Pediatr Blood Cancer. 2005;45(6):796–801.PubMedCrossRef
38.
Gómez-Román JJ, et al. Human herpesvirus-8 genes are expressed in pulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). Am J Surg Pathol. 2001;25(5):624–9.PubMedCrossRef
39.
40.
Zhang Y, et al. Inflammatory myofibroblastic tumor in lung with osteopulmonary arthropathy. Chin Med J. 2009;122(24):3094–6.PubMed
41.
Su LD, et al. Inflammatory myofibroblastic tumor: cytogenetic evidence supporting clonal origin. Mod Pathol. 1998;11(4):364–8.PubMed
42.
Treissman SP, et al. Omental-mesenteric inflammatory pseudotumor. Cytogenetic demonstration of genetic changes and monoclonality in one tumor. Cancer. 1994;73(5):1433–7.PubMedCrossRef
43.
44.
Lee JC, et al. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 2017;241(3):316–23.PubMedCrossRef
45.
Yamamoto H, et al. p53 mutation and MDM2 amplification in inflammatory myofibroblastic tumours. Histopathology. 2003;42(5):431–9.PubMedCrossRef
46.
Elpek G. Inflammatory myofibroblastic tumor of the liver: a diagnostic challenge. J Clin Transl Hepatol. 2014;2(1):53–7.PubMedPubMedCentral
47.
Mamone G, et al. Imaging of primary malignant tumors in non-cirrhotic liver. Diagn Interv Imaging. 2020;101(9):519–35.PubMedCrossRef
48.
Horger M, et al. Synchronous gastrointestinal and musculoskeletal manifestations of different subtypes of inflammatory myofibroblastic tumor: CT. MRI and pathological features. Eur Radiol. 2005;15(8):1713–6.PubMedCrossRef
49.
Zeng X, et al. The clinical and radiological characteristics of inflammatory myofibroblastic tumor occurring at unusual sites. Biomed Res Int. 2018;2018:5679634.PubMedPubMedCentralCrossRef
50.
Liu C, et al. Using CT texture analysis to differentiate between peripheral lung cancer and pulmonary inflammatory pseudotumor. BMC Med Imaging. 2020;20(1):75.PubMedPubMedCentralCrossRef
51.
Zheng S, et al. CT signs and differential diagnosis of peripheral lung cancer and inflammatory pseudotumor: a meta-analysis. J Healthc Eng. 2022;2022:3547070.PubMedPubMedCentralCrossRef
52.
Chen B, et al. Inflammatory myofibroblastic tumor of the urinary system on computed tomography at a high-volume institution in China. Urol Int. 2020;104(11-12):960–7.PubMedCrossRef
53.
54.
Oguz B, et al. Imaging of childhood inflammatory myofibroblastic tumor. Pediatr Radiol. 2015;45(11):1672–81.PubMedCrossRef
55.
Porrino J, et al. Update of pediatric soft tissue tumors with review of conventional MRI appearance-part 1: tumor-like lesions, adipocytic tumors, fibroblastic and myofibroblastic tumors, and perivascular tumors. Skelet Radiol. 2022;51(3):477–504.CrossRef
56.
Surabhi VR, et al. Inflammatory myofibroblastic tumors: current update. Radiol Clin N Am. 2016;54(3):553–63.PubMedCrossRef
57.
Weinberger, S.E. Inflammatory myofibroblastic tumo (plasma cell granuloma) of the lung. 2021 Aug, 20, 2021.
58.
Coffin CM, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14(6):569–76.PubMedCrossRef
59.
Griffin CA, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776–80.PubMed
60.
Bennett JA, et al. Inflammatory myofibroblastic tumor of the uterus: an immunohistochemical study of 23 cases. Am J Surg Pathol. 2020;44(11):1441–9.PubMedCrossRef
61.
Rao N, et al. Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition. J Natl Compr Cancer Netw. 2018;16(2):115–21.CrossRef
62.••
Casanova M, et al. Inflammatory myofibroblastic tumor: the experience of the European pediatric soft tissue sarcoma study group (EpSSG). Eur J Cancer. 2020;127:123–9. A multicenter study that confirmed approximately 50% of patients with IMT harboured ALK gene rearrangement, and proposed the utility of chemotherapies in IMT treatmentPubMedCrossRef
63.
Trahair T, et al. Crizotinib and surgery for long-term disease control in children and adolescents with ALK-positive inflammatory myofibroblastic tumors. JCO Precis. Oncol. 2019:3.
64.
Ono A, et al. Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity. Lung Cancer. 2016;99:151–4.PubMedCrossRef
65.
66.
Tsakiri K, et al. Crizotinib failure in a TPM4-ALK-rearranged inflammatory myofibroblastic tumor with an emerging ALK kinase domain mutation. JCO Precis Oncol. 2017;1:1–7.PubMedCrossRef
67.
Sunga CGG, et al. Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib. Cancer Rep (Hoboken). 2023;6(3):e1792.PubMedCrossRef
68.
Antonescu CR, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;39(7):957–67.PubMedPubMedCentralCrossRef
69.
Yamamoto H, et al. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours. Histopathology. 2020;76(5):774–8.PubMedCrossRef
70.
Cessna MH, et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol. 2002;15(9):931–8.PubMedCrossRef
71.
Cook JR, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25(11):1364–71.PubMedCrossRef
72.
Montgomery EA, et al. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol. 2006;30(12):1502–12.PubMedCrossRef
73.
Swain RS, et al. Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol. 2008;39(3):410–9.PubMedCrossRef
74.
Qiu X, Montgomery E, Sun B. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts. Hum Pathol. 2008;39(6):846–56.PubMedCrossRef
75.
Chan JK, Cheuk W, Shimizu M. Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol. 2001;25(6):761–8.PubMedCrossRef
76.
Clark SB, Alsubait S. Non small cell lung cancer. StatPearls: Tresure Island (FL); 2022.
77.
Khajuria O, Sharma N. Epigenetic targeting for lung cancer treatment via CRISPR/Cas9 technology. Advances Cancer Biol-Metastasis. 2021;3:100012.CrossRef
78.
79.
80.
81.
Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.PubMedCrossRef
82.
Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023;4(3):330–43.PubMedCrossRef
83.
84.
Childress MA. Understanding oncogenic tyrosine kinase fusion driven cancer: an investigation into inflammatory myofibroblastic tumor and the non-kinase fusion partner. 2018, Vanderbilt University: Nashville. Tennessee.
85.
Kazandjian D, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19(10):e5–11.PubMedPubMedCentralCrossRef
86.
Li J, et al. Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls. Curr Med Res Opin. 2019;35(1):105–11.PubMedCrossRef
87.
Hida T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39.PubMedCrossRef
88.
Peters S, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38.PubMedCrossRef
89.
Camidge DR, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–39.PubMedCrossRef
90.
Hayashi H, et al. First-line lorlatinib versus crizotinib in ALK-positive NSCLC: Japanese subgroup analysis of CROWN. JTO Clin Res Rep. 2023;4(4):100471.PubMedPubMedCentral
91.
92.
Schöffski P, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med. 2018;6(6):431–41.PubMedCrossRef
93.••
94.
Children's Oncology, G., I. National Cancer, and Pfizer, Crizotinib in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. 2018.
95.•
Pfizer, An investigational drug, Crizotinib (PF-02341066), is being studied in tumors, except non-small cell lung cancer, that are positive for anaplastic lymphoma kinase (ALK). 2023. The clinical trial that contributed to the approval of crizotinib in treating ALK+ IMT.
96.
Khozin S, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436–9.PubMedCrossRef
97.
Novartis, P. and Novartis, LDK378 versus chemotherapy in previously untreated patients with ALK rearranged non-small cell lung cancer. 2016.
98.
99.
Wang Z, et al. Durable clinical response to ALK tyrosine kinase inhibitors in epithelioid inflammatory myofibroblastic sarcoma harboring PRRC2B-ALK rearrangement: a case report. Front Oncol. 2022;12:761558.PubMedPubMedCentralCrossRef
100.
Zhang C, et al. Efficacy and resistance of ALK inhibitors in two inflammatory myofibroblastic tumor patients with ALK fusions assessed by whole exome and RNA sequencing. Onco Targets Ther. 2020;13:10335–42.PubMedPubMedCentralCrossRef
101.
102.
Hoffmann-La R. A study comparing alectinib with crizotinib in treatment-naive anaplastic lymphoma kinase-positive advanced non-small cell lung cancer participants; 2017.
103.
104.
Ariad, P. and Takeda, ALTA-1L study: a study of brigatinib versus crizotinib in anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) participants. 2020.
105.
Xu X, et al. ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: a case report. Oncol Lett. 2019;17(2):2370–6.PubMed
106.
Princess Maxima Center for Pediatric, O. and Takeda, Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors. 2021.
107.
Pfizer, A study of lorlatinib versus crizotinib in first line treatment of patients with ALK-positive NSCLC. 2020.
108.
Wong HH, et al. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib. Anti-Cancer Drugs. 2020;31(10):1106–10.PubMedCrossRef
109.
Yuan C, et al. Metastatic anaplastic lymphoma kinase-1 (ALK-1)-rearranged inflammatory myofibroblastic sarcoma to the brain with leptomeningeal involvement: favorable response to serial ALK inhibitors: a case report. Am J Case Rep. 2017;18:799–804.PubMedPubMedCentralCrossRef
110.•
Shaw AT, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–29.PubMedCrossRef
111.
112.
Ito K, et al. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): a multicenter retrospective cohort study. Eur J Cancer. 2021;145:183–93.PubMedCrossRef
113.
Miriam AG, et al. ALK non-small cell lung cancer sequence of treatment: a case report. Precision Cancer Med. 2021:5.
114.
Mologni L, et al. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget. 2015;6(8):5720–34.PubMedPubMedCentralCrossRef
115.
Gainor JF, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–33.PubMedPubMedCentralCrossRef
116.
Wang HY, Ho CC, Shih JY. Multiple acquired resistance mutations of the ALK tyrosine kinase domain after sequential use of ALK inhibitors. J Thorac Oncol. 2017;12(5):e49–51.PubMedCrossRef
117.
118.
119.
Zhu X, et al. Treatment, pathological characteristics, and prognosis of pulmonary inflammatory myofibroblastic tumor-a retrospective study of 8 cases. Front Oncol. 2022;12:840886.PubMedPubMedCentralCrossRef
120.
Mittal A, et al. Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour. Ecancermedicalscience. 2021;15:1215.PubMedPubMedCentral
121.
Brivio E, Zwaan CM. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: efficacy and side effects. Pediatr Blood Cancer. 2019;66(5):e27645.PubMedCrossRef
122.
Michels SYF, et al. ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. NPJ Precis Oncol. 2017;1(1):4.PubMedPubMedCentralCrossRef
123.
Mansfield AS, et al. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann Oncol. 2016;27(11):2111–7.PubMedPubMedCentralCrossRef
124.
Takeyasu Y, et al. Impact of ALK inhibitors in patients with ALK-rearranged nonlung solid tumors. JCO Precis Oncol. 2021:5.
125.
Saiki M, et al. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene. Jpn J Clin Oncol. 2017;47(12):1189–92.PubMedCrossRef
126.
Honda K, et al. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. Investig New Drugs. 2019;37(4):791–5.CrossRef
127.
Han Q, et al. Case report: early distant metastatic inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene: study of two typical cases and review of literature. Front Med (Lausanne). 2022;9:826705.PubMedCrossRef
128.
Spafford M, Lunn D, Graham P. Malignant inflammatory myofibroblastic tumor: a rare case presentation. J Surg Case Reports. 2022;2022(9)
129.
Fujiki T, et al. Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib. Pediatr Blood Cancer. 2023;70(4):e30172.CrossRef
Metadata
Title
Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor
Authors
Qi-An Wang
Huan-Wu Chen
Ren-Chin Wu
Chiao-En Wu
Publication date
08-11-2023
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 12/2023
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01144-6

Other articles of this Issue 12/2023

Current Treatment Options in Oncology 12/2023 Go to the issue

ReviewPaper

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer

ReviewPaper

Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer

ReviewPaper

Cardiovascular AEs of tyrosine kinase inhibitors in CML

ReviewPaper

Perioperative Immunotherapy in Non-Small Cell Lung Cancer

ReviewPaper

Updates in the management of malignant pleural mesothelioma

ReviewPaper

Precision medicine in urothelial carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits